Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial
Authors:
- 7 October 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (2) , 480-489
Abstract
After denosumab discontinuation, the rebound effect can lead to rapid bone loss and increased fracture risk. Identifying effective sequential therapies after denosumab discontinuation is crucial to mitigate these risks. We conducted the Denosumab Sequential Therapy (DST) trial, a two‐year, multicenter, open‐label, randomized controlled trial, conducted at a referral center and two affiliated hospitals in Taiwan. The DST trial enrolled 101 patients aged 50 years or older who received denosumab for at least 2 years (median: 2 years) and stratified the patients into four intervention groups to evaluate the effectiveness of three therapeutic strategies compared to continuous denosumab treatment. The four arms were as follows: (1) continued denosumab for 2 years (denosumab group); (2) two consecutive annual zoledronate infusions (annual‐zoledronate group); (3) one zoledronate infusion followed by a supervised medication‐free year (biennial‐zoledronate group); and (4) one zoledronate infusion followed by resumed denosumab (double‐switching group). The primary outcome was the percent change in the lumbar spine (LS) bone mineral density (BMD), total hip BMD (TH‐BMD), and femoral neck BMD (FN‐BMD). Secondary outcomes included changes in BTMs, the incidence of clinical fractures, and the need for rescue zoledronate in the biennial‐zoledronate group. LS‐BMD increased by 1.77% in the denosumab group, by 2.25% in the double‐switching group, while decreasing by 0.71% in the annual‐zoledronate group and by 2.76% in the biennial‐zoledronate group. One‐third of patients in the biennial‐zoledronate group showed LS‐BMD loss exceeding the least significant change (LSC), and 22% required rescue zoledronate infusions. Given the significant bone loss observed, a single zoledronate infusion followed by a medication‐free year is not recommended. Two consecutive zoledronate infusions and the double‐switching regimen with resumed denosumab showed promising BMD preservation, making them advisable clinical alternatives after denosumab discontinuation.Keywords
This publication has 43 references indexed in Scilit:
- Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density ReductionJAMA Network Open, 2024
- Guidelines for Reporting Outcomes in Trial ReportsJAMA, 2022
- Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real‐World StudiesJBMR Plus, 2022
- Ten‐Year Simulation of the Effects of Denosumab on Bone Remodeling in Human BiopsiesJBMR Plus, 2021
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized StudyJournal of Bone and Mineral Research, 2020
- A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass GainsJournal of Bone and Mineral Research, 2020
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical TrialJournal of Bone and Mineral Research, 2019
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its ExtensionJournal of Bone and Mineral Research, 2017
- Clinical Features of 24 Patients With Rebound‐Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional CasesJournal of Bone and Mineral Research, 2017
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011